advertisement
11.3.3 Apraclonidine, brimonidine (452)
Showing records 1 to 25
Display only abstracts from IGR 20-4 in classification 11.3.3 Apraclonidine, brimonidine
Search within classification 11.3.3 Apraclonidine, brimonidine94658 Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up
Yeh PH
Medicine 2021; 100: e26724 (IGR: 22-2)
94821 Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study
Gautam N; Kesavan K
Current Eye Research 2021; 0: 1-9 (IGR: 22-2)
94658 Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up
Cheng YC; Shie SS; Lee YS; Shen SC; Chen HS; Wu WC; Su WW
Medicine 2021; 100: e26724 (IGR: 22-2)
92597 Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
Sharma PK
Current Eye Research 2021; 0: 1-14 (IGR: 22-1)
92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
Schnichels S; Hurst J
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)
92597 Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
Chauhan MK
Current Eye Research 2021; 0: 1-14 (IGR: 22-1)
92528 Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles
de Vries JW; Ullah S; Frößl K; Gruszka A; Löscher M; Bartz-Schmidt KU; Spitzer MS; Herrmann A
ACS applied materials & interfaces 2021; 13: 9445-9456 (IGR: 22-1)
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Rodrigo MJ; Rodrigo MJ
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)
91036 Brimonidine-associated uveitis - a descriptive case series
Hopf S; Mercieca K
BMC Ophthalmology 2020; 20: 489 (IGR: 21-4)
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Cardiel MJ; Fraile JM
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)
91036 Brimonidine-associated uveitis - a descriptive case series
Pfeiffer N; Prokosch-Willing V
BMC Ophthalmology 2020; 20: 489 (IGR: 21-4)
91466 Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Mendez-Martinez S; Mendez-Martinez S; Martinez-Rincon T; Martinez-Rincon T; Subias M; Subias M; Polo V; Ruberte J; Ramirez T; Vispe E; Luna C; Mayoral JA; Garcia-Martin E
Biomaterials science 2020; 8: 6246-6260 (IGR: 21-4)
86172 Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty
Thrane VR
Journal of Glaucoma 2020; 29: 280-286 (IGR: 21-2)
86713 The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
Alonso RS
BMC pharmacology & toxicology 2020; 21: 24 (IGR: 21-2)
86750 Effect of brimonidine tartrate on basophil activation in glaucoma patients
Rosenfeld E
International Journal of Ophthalmology 2020; 13: 509-512 (IGR: 21-2)
86270 A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients
Inoue K
Japanese Journal of Ophthalmology 2020; 64: 103-113 (IGR: 21-2)
86843 A review of neuropsychiatric adverse events from topical ophthalmic brimonidine
Cimolai N
Human and Experimental Toxicology 2020; 39: 1279-1290 (IGR: 21-2)
86172 Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty
Thrane AS
Journal of Glaucoma 2020; 29: 280-286 (IGR: 21-2)
86713 The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
Solari HP
BMC pharmacology & toxicology 2020; 21: 24 (IGR: 21-2)
86270 A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients
Ishida K
Japanese Journal of Ophthalmology 2020; 64: 103-113 (IGR: 21-2)
86172 Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty
Thrane AS
Journal of Glaucoma 2020; 29: 280-286 (IGR: 21-2)
86750 Effect of brimonidine tartrate on basophil activation in glaucoma patients
Barequet D; Rabina G
International Journal of Ophthalmology 2020; 13: 509-512 (IGR: 21-2)
86172 Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty
Bergo C
Journal of Glaucoma 2020; 29: 280-286 (IGR: 21-2)
86713 The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations
de França Damasceno E
BMC pharmacology & toxicology 2020; 21: 24 (IGR: 21-2)
86270 A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients
Tomita G; Noma H
Japanese Journal of Ophthalmology 2020; 64: 103-113 (IGR: 21-2)
